Zenapax (Hoffmann-La Roche Inc) en es it fr

Zenapax (Hoffmann-La Roche Inc) Brand names, Zenapax (Hoffmann-La Roche Inc) Analogs

Zenapax (Hoffmann-La Roche Inc) Brand Names Mixture

  • No information avaliable

Zenapax (Hoffmann-La Roche Inc) Chemical_Formula

C6332H9808N1678O1989S42

Zenapax (Hoffmann-La Roche Inc) RX_link

http://www.rxlist.com/cgi/generic3/zenapax.htm

Zenapax (Hoffmann-La Roche Inc) fda sheet

Zenapax (Hoffmann-La Roche Inc) msds (material safety sheet)

Zenapax (Hoffmann-La Roche Inc) Synthesis Reference

Sequence listed in humanized anti-Tac, PNAS 1989 with Queen, C, Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods. 2005 May;36(1):69-83.

Zenapax (Hoffmann-La Roche Inc) Molecular Weight

142612.1

Zenapax (Hoffmann-La Roche Inc) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Zenapax (Hoffmann-La Roche Inc) H2O Solubility

No information avaliable

Zenapax (Hoffmann-La Roche Inc) State

Liquid

Zenapax (Hoffmann-La Roche Inc) LogP

-0.437

Zenapax (Hoffmann-La Roche Inc) Dosage Forms

Solution (IV)

Zenapax (Hoffmann-La Roche Inc) Indication

For prevention of renal transplant rejection

Zenapax (Hoffmann-La Roche Inc) Pharmacology

Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Zenapax (Hoffmann-La Roche Inc) Absorption

No information avaliable

Zenapax (Hoffmann-La Roche Inc) side effects and Toxicity

No information avaliable

Zenapax (Hoffmann-La Roche Inc) Patient Information

No information avaliable

Zenapax (Hoffmann-La Roche Inc) Organisms Affected

Humans and other mammals